Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

Eli Lilly has filed its highly-anticipated rheumatoid arthritis treatment baricitinib in the US, setting the clock ticking on a possible approval later this year. The orally-active drug is considered a blockbuster contender on the back of clinical

(Visited 2 times, 1 visits today)
6
Like
Save

Comments

Comments are disabled for this post.